At Biotts, our partnership with Bioton has been on an exciting journey towards revolutionizing transdermal insulin delivery. We are proud to share our key achievements so far and outline the path that lies ahead for this groundbreaking collaboration.
Key Achievements
- 55% Bioavailability: Our team has successfully achieved 55% bioavailability for transdermal insulin delivery. While lower than the 100% bioavailability of injections, this represents a significant stride towards providing a needle-free alternative for insulin administration.
- Large Molecule Delivery: We have accomplished the ability to deliver insulin molecules nearly 12 times larger than those currently possible with existing transdermal technologies. This breakthrough opens up new possibilities for the transdermal delivery of other large molecule drugs.
- Extended Dose Duration: A single 5-day transdermal insulin patch developed by our partnership can replace up to 20 insulin injections. This innovation enhances patient comfort, improves adherence, and reduces the frequency of administration, making diabetes management more convenient.
Next Steps and Future Plans
- Large Animal Studies: Building on our initial success, we plan to conduct further testing on large animals by the end of 2024. This crucial step will validate the efficacy and safety of our transdermal insulin delivery system in a more complex biological model.
- Clinical Trials: Following the completion of large animal studies, we aim to initiate clinical trials in early 2025. These trials will be conducted in parallel with regulatory submissions to both the FDA and EMA, with the goal of bringing our innovative transdermal insulin delivery system to market by 2027.
At Biotts, our partnership with Bioton remains committed to advancing transdermal drug delivery technologies. Our focus is on improving patient outcomes and quality of life through innovative, needle-free therapeutic solutions. We look forward to sharing more updates as we continue to push the boundaries of what’s possible in transdermal insulin delivery.
For more details, you can read the full article in Polish here:
https://www.pb.pl/amerykanie-poszukaja-kapitalu-dla-biottsa-1216704